Insiders Genome & Company

Equities

End-of-day quote Korea S.E. Other stock markets 23:00:00 20/05/2024 BST			5-day change	1st Jan Change
8,920 ^KRW	-2.62%		+16.91%	-28.58%

01-24	Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	CI
2023	Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	CI

No results for this search